Can Scleritis Be Cured?

Scleritis is a serious, potentially vision-threatening inflammatory condition affecting the sclera—the tough, fibrous outer layer of the eye. While it cannot be “cured” in the traditional sense—meaning permanently eradicated without risk of recurrence—it is highly treatable with appropriate, timely intervention. The primary goal of management is to suppress inflammation, prevent structural damage to the eye (such as scleral thinning, perforation, or secondary complications like uveitis or glaucoma), and preserve visual function.

Treatment typically begins with systemic corticosteroids, often administered orally or intravenously for moderate to severe cases. For patients who are steroid-dependent, experience adverse effects, or have refractory disease, immunomodulatory therapy—including methotrexate, mycophenolate mofetil, azathioprine, or biologic agents such as tumor necrosis factor (TNF) inhibitors—is frequently added or substituted. Local corticosteroid injections are generally avoided due to risks of scleral atrophy and perforation.

Importantly, scleritis is frequently associated with underlying systemic autoimmune disorders—most commonly rheumatoid arthritis, granulomatosis with polyangiitis, or systemic lupus erythematosus. Therefore, comprehensive evaluation by both ophthalmology and rheumatology is essential. Identifying and managing the systemic disease significantly improves ocular outcomes and reduces relapse risk.

With early diagnosis and adherence to a tailored therapeutic regimen, most patients achieve sustained remission. However, long-term monitoring remains critical: recurrence rates are substantial, particularly in posterior or necrotizing forms, and delayed treatment increases the risk of irreversible vision loss. Patient education, regular follow-up, and interdisciplinary care are cornerstones of successful management.